Reata Pharmaceuticals, Inc.
RETA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.91 | -0.28 | 0.73 | -0.09 |
| FCF Yield | -15.04% | -24.75% | -7.76% | -4.08% |
| EV / EBITDA | -5.42 | -2.07 | -14.42 | -20.53 |
| Quality | ||||
| ROIC | -59.02% | -35.71% | -28.10% | -58.16% |
| Gross Margin | 100.00% | 100.00% | 100.00% | -369.13% |
| Cash Conversion Ratio | 0.65 | 0.79 | 1.30 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | -37.37% | -24.33% | -44.79% | -17.98% |
| Free Cash Flow Growth | 12.44% | 26.68% | -27.36% | -200.52% |
| Safety | ||||
| Net Debt / EBITDA | -0.29 | 1.87 | 3.52 | 1.83 |
| Interest Coverage | -6.47 | -4.60 | -6.15 | -25.47 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -5.60 |